Metabolic Cut – Advanced
The Metabolic Cut – Advanced expands the Start protocol to five complementary compounds: a higher-dose GLP receptor agonist, 5-Amino-1MQ, injectable SLU-PP-332, the mitochondrial peptide MOTS-c and master-antioxidant Glutathione.
Built for deeper research into energy partitioning, fat oxidation, mitochondrial output and metabolic resilience – a complete bundled set at a single discounted price.
Original price was: 594,00 €.446,00 €Current price is: 446,00 €.
The expanded 5-part metabolic protocol: a GLP receptor agonist, 5-Amino-1MQ, injectable SLU-PP-332, MOTS-c and Glutathione.
What's included in this stack
Metabolic Cut - Advanced - Expanded Five-Compound Metabolic Investigation
Description
Mechanism of Action
The Metabolic Cut – Advanced bundle is designed for comprehensive investigation into multi-faceted metabolic regulation. GLP-3R (Rеtаtrutіdе) provides foundational systemic modulation through triple GLP-1/GIP/glucagon receptor agonism, while 5-Amino-1MQ and the injectable Slu-pp-332 are studied for their distinct influences on cellular energy metabolism and mitochondrial function. MOTS-c further contributes to research on mitochondrial homeostasis and insulin sensitivity, with Glutathione included to support cellular redox balance and resilience against oxidative stress, offering a synergistic platform for advanced metabolic research.
Benefits
- Exceptional Weight Reduction – Rеtаtrutіdе (GLP-3R) is researched for its capacity to induce substantial body weight reduction, including significant decreases in both subcutaneous and visceral fat mass.
- Comprehensive Metabolic Regulation – Rеtаtrutіdе (GLP-3R) is investigated for its triple agonist action on GLP-1, GIP, and glucagon receptors, promoting broad metabolic modulation, enhanced insulin secretion, and appetite suppression.
- Targeted Adipose Metabolism – 5-Amino-1MQ is studied for its selective inhibition of the NNMT enzyme, which is observed to reduce white fat accumulation and enhance lipolysis, thereby optimizing adipose tissue metabolism.
- Enhanced Fat Oxidation – Slu-pp-332 is researched as a selective PPARδ agonist, enhancing fatty acid β-oxidation and mitochondrial respiration to improve energy efficiency and fat utilization.
- Mitochondrial Biogenesis – MOTS-c and Slu-pp-332 are investigated for their roles in activating AMPK and PGC-1α signaling, respectively, leading to enhanced mitochondrial biogenesis and improved cellular energy production.
- Improved Glucose Sensitivity – Stack components are studied for their ability to enhance insulin sensitivity and glucose utilization, promoting improved glycemic control and metabolic homeostasis.
- Master Antioxidant Support – Glutathione is researched as the body’s master antioxidant, playing a critical role in neutralizing free radicals, supporting liver detoxification pathways, and maintaining cellular redox balance.
- Lean Mass Preservation – Components like Rеtаtrutіdе (GLP-3R) and 5-Amino-1MQ are investigated for their capacity to support the maintenance of lean muscle tissue during periods of significant fat loss.
Research Data
GLP-2T
| Study / Model | Reported effect |
| Human clinical trials (SURPASS program, T2DM) | ↓ HbA1c (up to -2.4%) and body weight (-12 kg over 40 weeks) vs insulin and Sеmаglutіdе. |
| Human clinical trials (obesity without diabetes) | 15-22% mean weight loss at 72 weeks; improved lipids and blood pressure. |
| Comparative RCTs (Tіrzеpаtіdе vs Sеmаglutіdе) | Higher efficacy in weight and glycemic outcomes; similar tolerability. |
| NAFLD / NASH models | ↓ hepatic steatosis and transaminases (ALT/AST); improved insulin response and mitochondrial function. |
| GLP-1/GIP receptor studies (preclinical) | Dual receptor activation → ↑ insulin secretion, ↓ appetite, ↑ energy efficiency. |
| Cardiometabolic outcomes (post-hoc human) | ↓ total cholesterol, LDL, triglycerides, CRP; improved insulin sensitivity. |
| Animal obesity / high-fat diet models | ↓ fat mass, ↑ thermogenesis and glucose tolerance. |
| Human tolerability studies (Phases 1-3) | Common mild effects: nausea, diarrhea; no serious hepatic or hematologic effects. |
| Long-term weight maintenance (extension trials) | >80% of weight reduction maintained after 88 weeks of continued use. |
5-Amino-1MQ
| Study / Model | Reported effect |
| Diet-induced obese mice (DIO model) | ↓ body weight by 40%, ↓ fat mass, ↑ lean mass without caloric restriction. |
| NNMT knockout comparison | Mimicked genetic NNMT deletion benefits: ↑ NAD+, ↑ SIRT1, ↑ mitochondrial respiration. |
| In vitro adipocyte culture | ↓ lipid accumulation, ↑ AMPK activation, ↓ inflammatory cytokines. |
| High-fat diet mouse study | ↓ fasting glucose and insulin levels, improved insulin tolerance. |
| Liver steatosis models | ↓ hepatic triglycerides and lipid deposition; ↑ mitochondrial biogenesis. |
| Combination NAD+ + 5-Amino-1MQ | Synergistic NAD+ increase and enhanced metabolic flexibility. |
| Neuroinflammation model | ↓ ROS generation, ↑ mitochondrial membrane potential in neuronal cells. |
Slu-pp-332
| Study/model | Reported effect |
| Mouse endurance models | ↑ Running time to exhaustion (+35%), ↑ ATP levels in muscle tissue |
| In vitro mitochondrial assays | ↑ OXPHOS complex activity (I-IV), ↓ ROS leakage |
| Rat fatigue recovery studies | ↓ Lactate accumulation, ↑ glycogen resynthesis post-exercise |
| Cellular oxidative stress models | ↑ GSH:GSSG ratio, ↓ lipid peroxidation markers |
| AMPK activation assays | ↑ p-AMPK and PGC-1α expression, ↑ mitochondrial density |
| High-fat diet mouse models | ↓ Fat accumulation, ↑ β-oxidation enzyme expression |
| Neuronal culture models | ↑ Mitochondrial membrane potential, ↓ oxidative apoptosis |
MOTS-c
| Study/model | Reported effect |
| Human observational studies (older adults) | ↓ endogenous MOTS-c levels correlate with insulin resistance and aging |
| Animal models (diet-induced obesity) | ↓ fat accumulation, ↑ insulin sensitivity, and restored glucose tolerance |
| Exercise physiology studies | ↑ endurance performance and mitochondrial gene expression in muscle |
| Cellular stress models | ↑ AMPK activation and mitochondrial ROS reduction under oxidative stress |
| High-fat diet mice | ↓ hepatic lipid accumulation and improved metabolic parameters |
| In vitro myocyte cultures | ↑ GLUT4 expression and glucose uptake after peptide exposure |
| Human pilot trial (2022) | Safe SubQ administration; improved fasting glucose and perceived energy |
| Longevity studies (aged mice) | ↑ median lifespan and improved skeletal muscle mitochondrial function |
Glutathione
| Study/model | Reported effect |
| Human trials (oral and IV administration) | ↑ Plasma GSH levels, ↓ oxidative biomarkers (MDA, 8-OHdG) |
| Animal oxidative stress models | ↓ Lipid peroxidation and improved mitochondrial GSH:GSSG ratio |
| Hepatotoxicity models (CCl4, acetaminophen) | ↓ ALT/AST, ↓ hepatic necrosis, improved antioxidant enzyme activity |
| Neurodegenerative disease models | Protection of dopaminergic neurons and ↓ oxidative stress markers |
| In vitro melanocyte cultures | ↓ Tyrosinase activity and melanin synthesis via GSH-mediated inhibition |
| Inflammatory models | ↓ TNF-α, IL-6, and CRP, supporting immunomodulatory roles |
| Pharmacokinetic assessments | ↑ Cellular uptake with liposomal and SubQ formulations |
Stack Suggestions
This bundle is suited for researchers investigating complex metabolic dysregulation, energy expenditure and cellular resilience in advanced research models, providing a robust framework for the interplay between incretin signaling, cellular energy pathways and antioxidant defense.
Pen Dosage Chart
GLP-2T
| GLP-2T Pen 5 mg | |
|---|---|
| Volume | 1.5 mL |
| mg/mL | 3.333 mg/mL |
| Click-to-Dose | 1 click = 0.033 mg |
| Example(s) | 10 clicks = 0.333 mg |
| GLP-2T Pen 10 mg | |
|---|---|
| Volume | 1 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 10 clicks = 1 mg |
| GLP-2T Pen 15 mg | |
|---|---|
| Volume | 1.5 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 10 clicks = 1 mg |
5-Amino-1MQ
| 5-Amino-1MQ Pen 100 mg | |
| Volume | 3.0 mL |
| mg/mL | 33.33 mg/mL |
| Click-to-Dose | 1 click = 0.33 mg |
| Example(s) | 15 clicks = 5 mg |
Slu-pp-332
| Slu-pp-332 Pen 5 mg | |
| Volume | 3.0 mL |
| mg/mL | 1.67 mg/mL |
| Click-to-Dose | 1 click = 0.017 mg |
| Example(s) | 10 clicks = 0.17 mg |
MOTS-c
| MOTS-c Pen 10 mg | |
| Volume | 2.0 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 20 clicks = 1 mg |
Glutathione
| Glutathione Pen 1500 mg | |
|---|---|
| Volume | 3 mL |
| mg/mL | 500 mg/mL |
| Click-to-Dose | 1 click = 5 mg |
| Example(s) | 10 clicks = 50 mg |
Dosage & Protocols Variations
GLP-2T
Standard Research Protocol
- Dose: 2.5 – 5 mg (variant 5 mg pen = 76–152 clicks / variant 10 mg pen = 25–50 clicks / variant 15 mg pen = 25–50 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1× weekly
- Cycle Interval: Optional 2-week pause
- Goal / Description: For basic metabolic modulation studies
Therapeutic Research Protocol
- Dose: 10 – 15 mg (variant 15 mg pen = 100–150 clicks)
- Duration: 24 – 48 weeks
- Frequency: 1× weekly
- Cycle Interval: Repeat after 1 month
- Goal / Description: Modeled on SURPASS/SURMOUNT designs; for long-term metabolic outcomes
Biohacker Microdosing
- Dose: 0.5 – 1 mg every 3 days (variant 5 mg pen = 15–30 clicks / variant 10 mg pen = 5–10 clicks / variant 15 mg pen = 5–10 clicks)
- Duration: 4 – 8 weeks
- Frequency: Every 3 days
- Cycle Interval: Repeat after 1 month
- Goal / Description: Used experimentally to assess mild appetite control and metabolic priming
Maintenance Phase
- Dose: 2.5 – 5 mg (variant 5 mg pen = 76–152 clicks / variant 10 mg pen = 25–50 clicks / variant 15 mg pen = 25–50 clicks)
- Duration: Variable
- Frequency: 1× weekly
- Cycle Interval: Continuous
- Goal / Description: Sustain achieved body composition and metabolic balance.
5-Amino-1MQ
Standard Research Protocol
- Dose: 5 – 10 mg daily (= 15–30 clicks)
- Duration: 2 – 4 weeks
- Frequency: Daily
- Cycle Interval: 2-week pause
- Goal / Description: For baseline NAD+ and fat metabolism studies.
Therapeutic Research Protocol
- Dose: 10 – 20 mg (= 30–61 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 4-week interval
- Goal / Description: Modeled on extended NNMT inhibition protocols in DIO models.
Biohacker Microdosing
- Dose: 2.5 – 5 mg (= 8–15 clicks)
- Duration: 4 weeks
- Frequency: Every other day
- Cycle Interval: Repeat monthly
- Goal / Description: Evaluates mild NAD+ upregulation and metabolic activation.
Mitochondrial Stack Protocol
- Dose: 5 mg 5-Amino-1MQ + 100 mg NAD+ (= 15 clicks)
- Duration: 4 weeks
- Frequency: 3× per week
- Cycle Interval: Repeatable
- Goal / Description: Synergistic design to study combined mitochondrial enhancement.
Slu-pp-332
Standard Metabolic Activation Protocol
- Dose: 0.25 – 0.5 mg (= 15–29 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 4-week rest
- Goal / Description: Evaluates activation of AMPK and mitochondrial biogenesis pathways in metabolic research models
Enhanced Lipid Oxidation Protocol
- Dose: 0.5 – 1 mg (= 29–59 clicks)
- Duration: 8 – 12 weeks
- Frequency: Every Other Day
- Cycle Interval: 8-week rest
- Goal / Description: Focused on lipid metabolism enhancement and sustained fat oxidation under controlled caloric intake studies
Biohacker Optimization Protocol
- Dose: 0.25 mg (= 15 clicks)
- Duration: ongoing
- Frequency: 1× daily (morning)
- Cycle Interval: None (microdosing schedule)
- Goal / Description: Applied to maintain consistent metabolic signaling and support mitochondrial output through low-dose continuous exposure
MOTS-c
Standard Metabolic Protocol
- Dose: 0.5 – 1 mg (= 10–20 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 4-week rest
- Goal / Description: Commonly used for metabolic regulation and insulin sensitivity studies
Performance & Endurance Protocol
- Dose: 1 mg (= 20 clicks)
- Duration: 8 – 12 weeks
- Frequency: Every Other Day
- Cycle Interval: 4-week rest
- Goal / Description: Applied in models focused on energy optimization and fatigue resistance
Mitochondrial Recovery Protocol
- Dose: 5 mg (= 100 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 8-week rest
- Goal / Description: Studied for mitochondrial repair and oxidative stress response
Glutathione
Standard Antioxidant Protocol
- Dose: 200 – 400 mg (= 40–80 clicks)
- Duration: 4 – 8 weeks
- Frequency: 3× weekly
- Cycle Interval: 4-week rest
- Goal / Description: ↑ Systemic antioxidant capacity, baseline redox support
Intensive Detoxification Protocol
- Dose: 500 – 600 mg (= 100–120 clicks)
- Duration: 4 weeks
- Frequency: 5× weekly
- Cycle Interval: 8-week rest
- Goal / Description: Rapid ↑ GSH levels for detoxification models, tissue saturation
Maintenance Protocol
- Dose: 150 mg (= 30 clicks)
- Duration: 8 – 12 weeks
- Frequency: 3× weekly
- Cycle Interval: 8-week rest
- Goal / Description: Long-term maintenance of improved GSH status
Possible Side Effects
This bundle combines multiple research compounds; the per-compound safety notes below apply. For laboratory research use only – not for human consumption.
GLP-2T
Tіrzеpаtіdе may cause mild and transient gastrointestinal symptoms in some research subjects.
The most common reactions include nausea, diarrhea, and reduced appetite, particularly during initial exposure. Occasional reports include constipation, vomiting, or abdominal discomfort, typically resolving as tolerance develops. Other possible effects include fatigue or transient increases in heart rate during activity.
All effects are reversible and dose-dependent. Proper titration minimizes occurrence.
5-Amino-1MQ
5-Amino-1MQ is generally well tolerated in preclinical studies.
Potential mild effects observed in animal and in vitro models include transient fatigue, mild nausea, or digestive discomfort related to metabolic acceleration.
High doses may cause temporary headaches due to increased NAD+ turnover and mitochondrial activity.
Localized redness or irritation may occur at the subcutaneous injection site.
All effects are dose-dependent and typically resolve after dosage adjustment.
Slu-pp-332
Slu-pp-332, as a research compound, may induce side effects in experimental models, primarily related to its metabolic activation. These reactions are generally mild and dose-dependent via oral administration. Monitoring is key in protocols.
Fatigue: Temporary energy fluctuations during adaptation.
Gastrointestinal Upset: Mild nausea or diarrhea at higher doses.
Headache: Occasional, possibly from metabolic shifts.
Muscle Cramps: Rare, linked to enhanced activity.
Hormonal Changes: Potential minor estrogen-related effects, though non-steroidal.
It is crucial to note that most side effects are transient. No serious adverse events reported in preclinical; long-term safety unknown.
MOTS-c
MOTS-c, as a research peptide regulating metabolism, may induce various side effects in experimental models, primarily related to its influence on energy systems. These effects are often dose-dependent and more prominent during initial administration. It’s crucial to monitor subjects closely, as subcutaneous delivery can sometimes cause localized reactions.
Injection Site Reactions: Commonly observed, manifesting as redness or swelling that resolves within hours. Rotating sites minimizes this.
Fatigue: A sense of lethargy reported early on, possibly due to metabolic shifts. It often resolves as homeostasis stabilizes.
Nausea: Mild gastrointestinal upset, linked to AMPK activation. Typically transient.
Headache: Occasional, attributed to vascular adjustments.
Most side effects are transient and manageable through dose adjustments in research settings. However, prolonged exposure warrants vigilance for potential hypersensitivity, though rare in controlled protocols.
Glutathione
Glutathione supplementation is generally well-tolerated due to its endogenous nature, but some individuals may experience side effects, particularly with higher doses or sensitive constitutions. The most common adverse reactions are related to gastrointestinal adjustments and administration site responses with subcutaneous injection protocols.
Gastrointestinal Effects: Mild nausea, abdominal cramping, bloating, and flatulence may occur, especially during the initial supplementation period. These symptoms typically resolve as the body adapts to increased glutathione levels. Some users report a metallic or sulfur-like taste, which is attributed to the cysteine component of the molecule.
Injection Site Reactions: With subcutaneous administration, mild redness, swelling, or irritation at the injection site may occur. These reactions are typically transient and resolve within 24-48 hours. Proper injection technique and site rotation can minimize these effects.
Allergic Reactions: Although rare, some individuals may experience allergic responses including skin rashes, hives, or in severe cases, difficulty breathing. Those with known sensitivities to sulfur-containing compounds should exercise particular caution.
Respiratory Considerations: Individuals with asthma or respiratory sensitivities should avoid inhaled forms, as glutathione may trigger bronchospasms or respiratory distress in predisposed individuals.
Headaches and Fatigue: Some users report mild headaches or temporary fatigue during initial supplementation, likely related to detoxification processes and cellular adjustments to enhanced antioxidant capacity.
It is important to note that most side effects are mild, transient, and resolve with continued use or dosage adjustment. However, individuals should discontinue use and consult healthcare providers if adverse reactions persist or worsen.
Product Attributes
Scientific References
GLP-2T
- Tіrzеpаtіdе once weekly for the treatment of obesity Human RCT
- Tіrzеpаtіdе : a systematic update Review
- Tіrzеpаtіdе versus sеmаglutіdе once weekly in patients with type 2 diabetes Human RCT
- Efficacy and safety of once-weekly tіrzеpаtіdе versus once-daily insulin degludec as add-on to metformin in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Human RCT
- Dual GIP and GLP-1 receptor agonist Tіrzеpаtіdе improves beta-cell function and insulin sensitivity in type 2 diabetes Human observational
- Effects of novel dual GIP and GLP-1 receptor agonist tіrzеpаtіdе on biomarkers of inflammation and cardiovascular risk in patients with type 2 diabetes Human RCT
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept Animal
- A long-term safety study of tіrzеpаtіdе (LY3298176) in participants with type 2 diabetes Human RCT
- Effect of tіrzеpаtіdе versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Human RCT
- Once-weekly sеmаglutіdе in adolescents with obesity (comparative to tіrzеpаtіdе context) Human RCT
5-Amino-1MQ
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Animal
- Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes mellitus Review
- What is 5-Amino-1MQ? uses & benefits of this special peptide Web
- 5-Amino-1MQ for beginners: dosage, benefits, and peptide stacks explained In vitro
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice Animal
- 5-Amino-1MQ Animal
- 5-Amino-1MQ vs. sеmаglutіdе: which is better for weight loss? Review
- 5-Amino-1MQ vs sеmаglutіdе: how they differ in weight loss approaches Review
- How 5-Amino-1MQ supports fat burn and metabolic health Web
- New insights on muscle strength: the role of inhibiting an enzyme that hinders NAD synthesis Animal
Slu-pp-332
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome Animal
- New hopes on “SLU-PP-332” as an effective agent for weight loss. Journal of Research in Endocrinology Animal
- Can SLU-PP-332 be a new drug to prevent COVID-19 In vitro
- SLU-PP-332 AND RELATED ERRα AS AGONISTS Review
- Unlocking the potential: SLU-PP-332 and the future of exercise Enhancement and Metabolic health Review
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome Animal
- Discover the Benefits and Risks of SLU PP 332 Review
- SLU-PP Peptide: Benefits, Dosage, and Metabolic Effects Explained Review
- SLU-PP-332: The Oral Peptide That Mimics Exercise and Boosts Metabolism Review
- What is SLU-PP-332? How does it Work? Review
MOTS-c
- Mitochondria-derived peptide MOTS-c restores mitochondrial … Animal
- MOTS-c Peptide | Benefits, Safety, & Buying Advice Animal
- Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet … Animal
- Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging … Animal
- MOTS-c Peptide Therapy: The Definitive 2025+ Blueprint for … Review
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic … Animal
- Mitochondria-derived peptide MOTS-c: effects and mechanisms … Animal
- MOTS-c Peptide: Benefits, Mechanism, and Side Effects Explained Review
- What Is MOTS-C? Mitochondrial Peptide for Anti-Aging Explained Review
- MOTS-c Peptide: Mechanism, Benefits, and Research Applications Review
Glutathione
- Randomized controlled trial of oral glutathione supplementation on body stores of glutathione Human RCT
- Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function Human RCT
- Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression Animal
- Glutathione system enhancement for cardiac protection: pharmacological and clinical data from bench-to-bedside Observational
- Randomized clinical trial of how long-term glutathione supplementation improves lipid metabolism in obese patients with nonalcoholic fatty liver disease Human RCT
- ALSUntangled no. 52: glutathione Human RCT
- Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, clinical trial Human observational
- Systemic glutathione as a skin-whitening agent in adults Human RCT
- Clinical evaluation of glutathione concentrations after consumption of S-acetylglutathione: a pilot study Human observational
- Development of a mouse model expressing a bifunctional glutathione-synthesizing enzyme to study glutathione limitation in vivo Animal
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
